Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00736749 : Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
AgesMin: N/A Max: N/A
Inclusion Criteria:

- The patient must be enrolled on a frontline COG therapeutic trial for treatment of a
primary malignancy and is nearing completion of or has recently completed protocol
treatment (within the past 180 days)*; or the patient must have been enrolled on a COG
(or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term
follow-up by ALTE05N1

- Hodgkin lymphoma

- CCG-5942

- POG-9425

- POG-9426

- COG-AHOD0031

- Brain tumor

- CCG-A9961

- Acute lymphoblastic leukemia

- POG-9404

- Rhabdomyosarcoma



- Note: For purposes of enrollment onto this study, completion of treatment is
defined as the date protocol therapy was terminated as reported (or will be
reported) on this patient's last "Reporting Period Worksheet/CRF" for their
frontline therapeutic protocol; patients become eligible as they approach this
date, and remain eligible for 180 days following the date that protocol therapy
was terminated; early termination of protocol therapy per the decision of the
patient, family and/or investigator does NOT preclude enrollment on this study

- Note: For purposes of eligibility for ALTE05N1, "early termination of protocol
therapy" means that the patient has finished protocol therapy and will not
receive further treatment; patients whose therapy is terminated early due to
toxicity or who opt out of an end-of-therapy randomization (e.g., randomization
to continue with an experimental agent vs. no further treatment) are eligible
because they will not be receiving further therapy; however, a patient who is
removed from protocol therapy or opts to discontinue protocol participation early
in the course of treatment (e.g., following Induction) is not eligible

- The patient must reside in the U.S. on the date of enrollment to ALTE05N1

- All patients and/or their parents or legal guardians must sign a written informed

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557